DrugBiological
Peginterferon beta-1a clinical trials
Also written Plegridy and BIIB017.
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Studies by the year they started
14 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 4
Biogen (10) · Food and Drug Administration (FDA) (1) · Pontificia Universidad Catolica de Chile (1) · Holy Name Medical Center, Inc. (1) · Johns Hopkins University (1)
Often tested with
Tested in the same studies.
Interferon beta-1a (3) · Interferon beta-1b (1) · Dimethyl Fumarate (1) · Prednisone (1) · Acetaminophen (1)
Studies
Open first, then newest update. How each study uses peginterferon beta-1a is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisActive, not recruitingPhase 3BiogenNCT03958877Written as BIIB017 (peginterferon beta-1a)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A ProductsCompletedPhase 1Food and Drug Administration (FDA)NCT04183491Written as Peginterferon beta-1a
- Plegridy Satisfaction Study in ParticipantsCompletedPhase 4BiogenNCT02587065Written as peginterferon beta-1a
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsTerminatedPhase 3BiogenNCT03870763Written as Peginterferon Beta-1a
- The Containing Coronavirus Disease 19 (COVID-19) TrialCompletedPhase 3Pontificia Universidad Catolica de ChileNCT04552379Written as Peginterferon beta-1a
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedPhase 4BiogenNCT03177083Written as peginterferon beta-1a
- Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side EffectsStatus unknownPhase 4Holy Name Medical Center, Inc.NCT03424733Written as Plegridy
- Long-Term Safety and Efficacy Study of Peginterferon Beta-1aCompletedPhase 3BiogenNCT01332019Written as peginterferon beta-1a
- Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy VolunteersCompletedPhase 1BiogenNCT02269930Written as peginterferon beta-1a
- Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.CompletedPhase 1BiogenNCT01978652Written as Peginterferon Beta-1a
- Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisCompletedPhase 3BiogenNCT00906399Written as BIIB017 (peginterferon beta-1a)
- Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple SclerosisWithdrawnPhase 3Johns Hopkins UniversityNCT01337427Written as BIIB017
- A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy VolunteersCompletedPhase 1BiogenNCT01119781Written as BIIB017(peginterferon beta-1a)
- A Multiple Dose Safety Study of PEG-IFN in Healthy VolunteersCompletedPhase 1BiogenNCT02125578Written as BIIB017 (PEGylated Interferon Beta-1a)
Given in every arm · 3 — peginterferon beta-1a is usual care beside what is tested
- Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)CompletedPhase 3BiogenNCT01939002Written as BIIB017
- Brimonidine Tartrate for the Treatment of Injection Related ErythemaWithdrawnPhase 4BiogenNCT02568111Written as peginterferon beta-1a
- Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon TherapyWithdrawnPhase 4BiogenNCT02234869Written as BIIB017 (Peginterferon beta-1a)
Codes
What other systems call peginterferon beta-1a · ClinicalTrials.gg INT004350
- MeSH (NLM) C428112peginterferon beta-1aOne source NLM
- UNII (FDA) I8309403R0PEGINTERFERON BETA-1AConfirmed FDA, NLM, Wikidata
- RxNorm 1546168Confirmed FDA, Wikidata
- Wikidata Q17126885peginterferon beta-1aConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170298Peginterferon Beta-1AOne source FDA
- DrugBank DB09122One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C428112 | peginterferon beta-1a | One source NLM |
| UNII (FDA) | I8309403R0 | PEGINTERFERON BETA-1A | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1546168 | — | Confirmed FDA, Wikidata |
| Wikidata | Q17126885 | peginterferon beta-1a | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170298 | Peginterferon Beta-1A | One source FDA |
| DrugBank | DB09122 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.